Financial Highlights
Financial Highlights
Boehringer Ingelheim Group of companies
Financial Highlights
Financial Highlights
| Boehringer Ingelheim group of companies | 2014 | 2013 | Change |
|---|---|---|---|
| Net sales | 13,317 | 14,065 | -5% |
| Net sales by region | |||
| Europe | 31% | 30% | |
| Americas | 44% | 46% | |
| Asia, Australasia, Africa | 25% | 24% | |
| by business | |||
| Prescription Medicines | 76% | 77% | |
| Consumer Health Care | 11% | 11% | |
| Animal Health | 8% | 8% | |
| Biopharmaceuticals | 4% | 3% | |
| Industrial Customers and other sales | 1% | 1% | |
| Research and Development | 2,654 | 2,743 | -3% |
| Personnel costs | 4,116 | 4,071 | +1% |
| Average number of employees | 47,743 | 47,492 | +1% |
| Operating income | 2,140 | 2,114 | +1% |
| Operating income as % of net sales | 16.1% | 15% | |
| Income after taxes | 1,047 | 1,324 | -21% |
| Income after taxes as % of net sales | 7.9% | 9.4% | |
| Shareholders' equity | 8,111 | 7,122 | +14% |
| Return on shareholders' equity | 14.7% | 21.4% | |
| Cash Flow | 1,850 | 2,129 | -13% |
| Investments in tangible assets | 548 | 558 | -2% |
| Depreciation of tangible assets | 449 | 640 | -30% |
Amounts in millions of EUR, unless otherwise indicated